Literature DB >> 9367476

A randomized, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxemic respiratory failure.

R W Day1, E M Allen, M K Witte.   

Abstract

STUDY
OBJECTIVE: To determine whether 24 h of inhaled nitric oxide improves oxygenation greater than conventional therapy alone in children with acute hypoxemic respiratory failure.
DESIGN: Prospective, randomized, controlled study.
SETTING: Twenty-six-bed pediatric ICU in a tertiary children's hospital. PATIENTS: Twenty-four patients with acute bilateral lung disease requiring a positive-end expiratory pressure >6 cm H2O and a fraction of inspired oxygen >0.5 for >12 h.
INTERVENTIONS: Twelve patients were treated with 10 ppm inhaled nitric oxide from the onset of randomization and 12 control patients were initially maintained on a regimen of conventional therapy alone. After a period of 24 h, control patients were also treated with 10 ppm inhaled nitric oxide. Hemodynamic and blood gas measurements were performed at baseline, at 1 h after randomization, and at 24-h intervals for 2 days. MEASUREMENTS AND
RESULTS: Inhaled nitric oxide decreased the ratio of pulmonary to systemic vascular resistance and improved oxygenation indexes during the initial hour following randomization. However, 24 h after randomization, the oxygenation indexes of 11 surviving treated patients were not improved in comparison to baseline or the oxygenation indexes of 10 surviving control patients. Oxygenation indexes acutely improved in control patients when inhaled nitric oxide was started after 24 h of conventional therapy. Oxygenation indexes remained improved in the initial control patients after 24 h of inhaled nitric oxide.
CONCLUSIONS: Pulmonary vascular resistance and systemic oxygenation are acutely improved by 10 ppm inhaled nitric oxide in some children with severe lung disease. However, a sustained improvement in oxygenation may not occur during prolonged therapy. Thus, inhaled nitric oxide may have a limited therapeutic role in children with acute hypoxemic respiratory failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367476     DOI: 10.1378/chest.112.5.1324

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Extra corporeal membrane oxygenation and plasmapheresis for pulmonary hemorrhage in microscopic polyangiitis.

Authors:  Hemant Shyam Agarwal; Mary Barraza Taylor; Marek Janusz Grzeszczak; Harold Newt Lovvorn; Tracy Earl Hunley; Kathy Jabs; Venkatramanan Shankar
Journal:  Pediatr Nephrol       Date:  2005-02-16       Impact factor: 3.714

Review 2.  Inhaled pulmonary vasodilators: a narrative review.

Authors:  Kai Liu; Huan Wang; Shen-Ji Yu; Guo-Wei Tu; Zhe Luo
Journal:  Ann Transl Med       Date:  2021-04

3.  A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children's Hospital, 2011-2015: A retrospective cohort study.

Authors:  S Padayachee; S Salie
Journal:  South Afr J Crit Care       Date:  2021-08-06

Review 4.  Role of Inhaled Nitric Oxide in the Management of Severe Acute Respiratory Distress Syndrome.

Authors:  Juliette Lucinda Hunt; Ronald A Bronicki; Nick Anas
Journal:  Front Pediatr       Date:  2016-08-02       Impact factor: 3.418

Review 5.  Management of paediatric acute respiratory distress syndrome.

Authors:  N Schneider; M Johnson
Journal:  BJA Educ       Date:  2022-06-22

6.  Inhaled Nitric Oxide Use in Pediatric Hypoxemic Respiratory Failure.

Authors:  John T Berger; Aline B Maddux; Ron W Reeder; Russell Banks; Peter M Mourani; Robert A Berg; Joseph A Carcillo; Todd Carpenter; Mark W Hall; Kathleen L Meert; Patrick S McQuillen; Murray M Pollack; Anil Sapru; Andrew R Yates; Daniel A Notterman; Richard Holubkov; J Michael Dean; David L Wessel
Journal:  Pediatr Crit Care Med       Date:  2020-08       Impact factor: 3.971

Review 7.  Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults.

Authors:  Fabienne Gebistorf; Oliver Karam; Jørn Wetterslev; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2016-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.